Literature review reveals distinct pediatric presentation of paroxysmal nocturnal hemoglobinuria, suggesting urgent need for tailored clinical approaches.
Key Points
Pediatric paroxysmal nocturnal hemoglobinuria primarily presents with bone marrow failure syndromes rather than classic hemolytic features.
Diagnosis is improved through high-sensitivity flow cytometry, allowing for early identification in small clone sizes.
Complement inhibitors like eculizumab and ravulizumab have significantly enhanced survival rates and reduced morbidity in pediatric patients.
Hematopoietic cell transplantation remains the only curative approach, but is typically reserved for select pediatric patients.